First-ever Optical Blood Pressure Monitoring System Now Available in the United Kingdom. Aktiia’s clinically validated Optical Blood Pressure Monitoring technology estimates blood pressure accurately, automatically, and painlessly, by analyzing signals from the wearer’s wrist.
Digital health veteran, Michael Kisch, joins innovative automated blood pressure monitoring pioneer.
Aktiia, a Swiss-US startup, has developed a wrist-worn optical blood pressure monitor that can automatically take measurements around the clock without requiring a specific arm position.
Aktiia, a Swiss-US startup that has developed an optical blood pressure monitor at the wrist, has raised an additional CHF 6 million in funding to bring its product to market.
“Maker of wearable continuous blood pressure monitor, Aktiia, today launched their 24/7 automated blood pressure monitoring system that gathers data during the day and while the user is asleep. Aktiia has received its CE mark as a Class lla medical device, meaning that the device has been assessed to meet safety, health and environmental protection requirements in Europe.”
“Accurate and validated Cuffless products like Aktiia are big step forward and represent the future of how blood pressure will be monitored outside a physician’s office.”
“Swiss startup Aktiia has beaten Fitbit, Apple and other tech giants to become the first company to get regulatory approval to sell a wearable bracelet which measures blood pressure.”
“Solà predicts that the bracelet could eventually be a game-changer for ambulatory blood pressure monitoring (ABPM), where overnight readings could be taken without the discomfort and disruption of periodic cuff inflations with current systems.”
“Aktiia’s bracelet and algorithms have now been validated in clinical trials against arterial lines (the gold standard for clinical reference) and in ambulatory settings. Never before has it been possible to measure blood pressure profiles, at any time, over long periods. This valuable and unique dataset will allow for broader insights into the diagnosis and treatment of hypertension, the largest epidemic of humankind.”
“The experimental data of this initial study showed error figures within 1 ± 7 mmHg, which are smaller than the threshold of 5 ± 8 mmHg typically accepted in clinical investigations… Having an optical, non-invasive, and cuffless blood pressure monitoring technology would improve the lives of many patients.”